ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

By A. Catapano, Željko Reiner, Guy G De Backer, Ian Graham, M. Taskinen, Olov Wiklund, S. Agewall, Eduardo Alegría, M. J. Chapman, P. Durrington and 8 more. Atherosclerosis, 2011

2,826 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/75a4147a9341ef683a4b4ee1cc583bb77768e927

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

In Endocrinology, Diabetes and Metabolism

In Surgery

Citations in the corpus

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013, background): “Statins are the drug of first choice because of the huge and robust bodyof evidence for statin-mediated reduction in major cardiovascular events.(6,7,25) The introduction of statins has also reduced CHD events in individuals with FH in observational studies,(3,4) such that with treatment before onse”
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “Total risk estimation using multiple risk factors (such as SCORE) is recommended for asymptomatic adults without evidence of CVD.”
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012, neutral): “This treatment should be started early during admission, as this increases patient adherence after discharge, and given at high doses, as this is associated with early and sustained clinical benefits.(270) The treatment goal is an LDL-cholesterol concentration of ,1.”
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med (2016, background): “The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).”